中国医学科学院药物研究所-九游官网下载

2007年毕业于浙江大学药学院，获得学士学位。同年于协和医学院医药生物技术研究所攻读博士学位，2012年毕业后一直任职于药物研究所。主要从事抗肿瘤药物的机制研究和小分子抗肿瘤药物的研发，包括ido, pd-1/pd-l1，kras，cdk8和pi3k/hadc等等。发表sci一作文章10余篇；参与申请国内外专利20余项，获得授权专利8项。主持和参与多项科研项目，包括：国家自然科学基金青年项目、药物所基本科研业务费、十三五创新药物重大科技专项、创新工程重大协同创新项目和国家自然科学基金面上项目等。

肿瘤药理，肿瘤免疫，抗肿瘤药物研发

[1] c. zhou1, f. lai1, sheng, x. chen, y. li, z. feng, design, synthesis and biological evaluation of phenyl urea derivatives as ido1 inhibitors, molecules, 25 (2020).
[2] y. zang1, f. lai1, j. fu, c. li, j. ma, c. chen, k. liu, t. zhang, x. chen, d. zhang, novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies, eur j med chem, 190 (2020) 112079.
[3] g. cui1, f. lai1, x. wang, x. chen, b. xu, design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as ido1/tdo dual inhibitors, eur j med chem, 188 (2020) 111985.
[4] k. zhang1, f. lai1, s. lin, m. ji, j. zhang, y. zhang, j. jin, r. fu, d. wu, h. tian, n. xue, l. sheng, x. zou, y. li, x. chen, h. xu, design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases, j med chem, 62 (2019) 6992-7014.
[5] n. xue1, f. lai1, t. du, m. ji, d. liu, c. yan, s. zhang, x. yu, j. jin, x. chen, chaperone-mediated autophagy degradation of igf-1rbeta induced by nvp-auy922 in pancreatic cancer, cell mol life sci, 76 (2019) 3433-3447.
[6] j. jin1, m. ji, r. fu, m. wang, n. xue, q. xiao, j. hu, x. wang, f. lai*, d. yin*, x. chen*, sphingosine-1-phosphate receptor subtype 1 (s1p1) modulator immh001 regulates adjuvant- and collagen-induced arthritis, front pharmacol, 10 (2019) 1085.
[7] q. zhang1, s. xu1, f. lai1, y. wang, n. zhang, m. nazare, h.y. hu, rapid synthesis of gamma-halide/pseudohalide-substituted cyanine sensors with programmed generation of singlet oxygen, org lett, 21 (2019) 2121-2125.
[8] y. he1, j. wen, q. cui, f. lai*, d. yin*, h. cui*, quantitative evaluation of in vivo target efficacy of anti-tumor agents via an immunofluorescence and edu labeling strategy, front pharmacol, 9 (2018) 812.
[9] f. lai1, z. shen1, h. wen, j. chen, x. zhang, p. lin, d. yin, h. cui, x. chen, a morphological identification cell cytotoxicity assay using cytoplasm-localized fluorescent probe (clfp) to distinguish living and dead cells, biochem biophys res commun, 482 (2017) 257-263.
[10] f. lai1, q. liu1, x. liu, m. ji, p. xie, x. chen, lxy6090 - a novel manassantin a derivative - limits breast cancer growth through hypoxia-inducible factor-1 inhibition, onco targets ther, 9 (2016) 3829-3840.
[11] f. lai1, n. madan, q1. ye, q. duan, z. li, s. wang, s. si, z. xie, identification of a mutant alpha1 na/k-atpase that pumps but is defective in signal transduction, j biol chem, 288 (2013) 13295-13304.
[12] q. ye1, f. lai1, m. banerjee, q. duan, z. li, s. si, z. xie, expression of mutant alpha1 na/k-atpase defective in conformational transition attenuates src-mediated signal transduction, j biol chem, 288 (2013) 5803-5814.
[13] y. xu1, f. lai1, y. xu, y. wu, q. liu, n. li, y. wei, t. feng, z. zheng, w. jiang, l. yu, b. hong, s. si, mycophenolic acid induces atp-binding cassette transporter a1 (abca1) expression through the ppargamma-lxralpha-abca1 pathway, biochem biophys res commun, 414 (2011) 779-782.

1.《中国药用植物志》艾铁民主编，中国科学出版社，2016年
2.《中华医学百科全书 肿瘤学（五）》，石远凯、刘德培主编，中国协和医科大学出版社，2020年

1. 苄苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。申请日期：2017.05.23. 授权日期：2021.03.09（美国）。
2. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。申请日期：2017.05.23. 授权日期：2020.11.03（俄罗斯）. 授权日期：2021.04.13（美国）。
3. 溴代苄醚衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,张莉婧,杨阳,来芳芳,季鸣,周川,郑义,薛妮娜,李凌。申请日期：2017.05.23。
4. 苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,周川,来芳芳,季鸣,金小锋,薛妮娜,郑义,陈浩,李凌。申请日期：2017.05.23. 授权日期：2021.01.05（美国）。
5. 苄苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。申请日期：2017.05.23。
6. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。申请日期：2017.05.23。

2020年，“梁周黄于刘青年科技奖”-三等奖，药物所